Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
66.91
+0.36 (0.54%)
At close: Feb 4, 2025, 4:00 PM
68.59
+1.68 (2.51%)
Pre-market: Feb 5, 2025, 8:37 AM EST
Corcept Therapeutics Employees
Corcept Therapeutics had 352 employees as of December 31, 2023. The number of employees increased by 53 or 17.73% compared to the previous year.
Employees
352
Change (1Y)
53
Growth (1Y)
17.73%
Revenue / Employee
$1,785,668
Profits / Employee
$399,111
Market Cap
7.01B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
CORT News
- 7 days ago - Big Money Keeps Buying Corcept - FXEmpire
- 11 days ago - Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm - PRNewsWire
- 13 days ago - Corcept Therapeutics Generating Strong Revenue And Profit Growth - Seeking Alpha
- 5 weeks ago - Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism - Business Wire
- 7 weeks ago - Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - Business Wire
- 7 weeks ago - Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes - Business Wire
- 7 weeks ago - Corcept Therapeutics' ALS drug fails in mid-stage trial - Reuters
- 7 weeks ago - Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) - Business Wire